Overview

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®
Phase:
Phase 4
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
(T,G)-A-L
Glatiramer Acetate
Interferon beta-1a
Interferon beta-1b